(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/148598 Al 16 August 2018 (16.08.2018) W !P O PCT (51) International Patent Classification: WARD, Carl, C. 1612 Buena Avenue, Berkeley, CA A61K 36/48 (2006.01) C07C 45/00 (2006.01) 94703 (US). A61K 36/484 (2006.01) C07C 45/41 (2006.01) (74) Agent: TERRANOVA, Zachary, L. et al; Mintz Levin A61P 35/00 (2006.01) C07C 45/45 (2006.01) Cohn Ferris Glovsky And Popeo, P.C., One Financial Cen (21) International Application Number: ter, Boston, MA 021 11 (US). PCT/US20 18/0 17702 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 09 February 2018 (09.02.2018) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/457,709 10 February 2017 (10.02.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: THE REGENTS OF THE UNIVERSITY OF SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Floor, Oakland, CA 94607-5200 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: NOMURA, Daniel, K.; 4532 Davenport Av kind of regional protection available): ARIPO (BW, GH, enue, Berkeley, CA 94619 (US). ROBERTS, Lindsay, S.; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 337 S. Fremont St. #321, San Mateo, CA 94401 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: COMPOSITIONS FOR TREATING BREAST CANCER 231 !VIFP cell survival > 0.01 0.1 1 10 100 licocha!cone (µ Μ) FIG. 5 (57) Abstract: Disclosed herein are compositions useful for inhibiting prostaglandin reductase 1(PTGRl ) activity. Further provided is a method of treating cancer, the method including administering to a subject in need thereof an effective amount of a PTGRl inhibitor. In another aspect is provided a method of treating triple negative breast cancer, the method including administering to a subject in need thereof an effective amount of a PTGRl inhibitor. In another aspect is provided a pharmaceutical composition including a PTGRl inhibitor and a pharmaceutically acceptable excipient. In preferred embodiments, the PTGRl inhibitor is a compound described herein. [Continued on nextpage] WO 2018/148598 Al llll II II 11III II I 11III II 11II I III II I II MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) COMPOSITIONS FOR TREATING BREAST CANCER CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 62/457,709, filed February 10, 2017, which is incorporated herein by reference in its entirety and for all purposes. REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII FILE [0002] The Sequence Listing written in file 052103-501001WO Sequence Listing_ST25.txt, created January 22, 2018, 4,768 bytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference. STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT [0003] This invention was made with government support under CA1 72667 awarded by the National Institutes of Health and under W81XWH-15-1-0050 awarded by the ARMY/MRMC. The government has certain rights in the invention. BACKGROUND [0004] In the United States, it is estimated that over 200,000 women will be diagnosed with breast cancer and nearly 40,000 women will die of breast cancer in 2016. Studies over the past decade have uncovered certain breast cancer cell-types, such as estrogen/progesterone/HER2 receptor (ER/PR/HER2)-negative (triple-negative) breast cancers (TNBCs) that show poor prognosis and chemotherapy-resistance within breast tumors. Eliminating these breast cancer types are critical in reducing the mortality associated with breast cancer. Disclosed herein, inter alia, are solutions to these and other problems in the art. BRIEF SUMMARY [0005] In an aspect is provided a compound having the formula: [0006] R is independently halogen, -CXS, -CHX^, -CH2X 1, -OCX^, - 1 D A B (0 A B (0 A B OCH2X , -OCHX , -CN, -SOniR , -SOviNR R , - H C ) R R , -N ) m i , - R R , (0 (0 (0 A B D A S0 D A (0 A (0)0 - C ) R , - C )-OR , - C ) R R , -OR , - R 2R , - R C ) R , - R C A R , - R 0 R , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R substituents may optionally bejoined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. The symbol zl is an integer from 0 to 5. R 2 is 2 2 2 2 independently halogen, -CX , -CHX 2 , -CH 2 X , -OCX 3 , - 2 2 2D 2 A 2B (0 2 A 2 B (0) , 2 A 2 B OCH2X , -OCHX 2, -CN, -SO„2R , -SO 2 N R R , -NHC )NR R , -N m 2 -NR R , (0 2 (0 2 (0 2 A 2 B 2 D 2A S0 2 D 2 A (0 2 2 A (0)0 - C ) R , - C )-OR , - C )NR R , -OR , -NR 2R , -NR C ) R , -NR C 2 2 A 2 R , -NR O R , -N 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 2 substituents may optionally bejoined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. The symbol z2 is an integer from 0 to 5. Each R A , R B , R , R D , R 2 A , R 2 B , R 2 , and R 2D is independently hydrogen, -CX 3 , -CN, -COOH, -CONH2, -CHX 2 , -CH 2 X , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R A and R B substituents bonded to the same nitrogen atom may optionally bejoined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R 2 A and R 2 B substituents bonded to the same nitrogen atom may optionally bejoined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl. Each X , X 1 , and X 2 is independently -F, -CI, -Br, or -I. The symbols nl and n2 are independently an integer from 0 to 4 . The symbols ml, m2, vl, and v2 are independently an integer from 1to 2 . [0007] In an aspect is provided a PTGR1 inhibitor. In embodiments, the PTGR1 inhibitor is a compound described herein. [0008] In an aspect is provided a method of treating cancer, the method including administering to a subject in need thereof an effective amount of a PTGRl inhibitor. In embodiments, the PTGRl inhibitor is a compound described herein. [0009] In an aspect is provided a method of treating triple negative breast cancer, the method including administering to a subject in need thereof an effective amount of a PTGRl inhibitor. In embodiments, the PTGRl inhibitor is a compound described herein. [0010] In an aspect is provided a method of treating cancer including administering to a subject in need thereof an effective amount of a compound described herein. [0011] In an aspect is provided a method of treating a disease associated with PTGRl activity including administering to a subject in need thereof an effective amount of a PTGRl inhibitor. [0012] In an aspect is provided a method of inhibiting PTGRl activity including contacting the PTGRl with a PTGRl inhibitor. [0013] In an aspect is provided a method of inhibiting PTGRl activity including contacting the PTGRl with a compound described herein. [0014] In an aspect is provided a PTGRl protein covalently bonded to a PTGRl inhibitor (a PTGRl protein-PTGRl inhibitor complex). [0015] In an aspect is provided a PTGRl protein covalently bonded to a compound described herein. BRIEF DESCRIPTION OF THE DRAWINGS [0016] FIGS. 1A-1C. Screening a library of drugs and drug candidates in TNBC cells. (FIGS. ΙΑ,ΙΒ) A library of drugs and drug candidates were screened in 231MFP and HCC38 TNBC cell lines for impairments in serum-free cell survival. (FIG. 1C) Cell survival of drugs and drug candidates that reproducibly and significantly impaired 231MFP, HCC38, and HCC70 viability by >50 % .